Suchergebnisse - "Gyawali, Bishal"

PubPharm (9)

1

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer : a meta-analysis of randomized controlled trials

enthalten in: Breast cancer research and treatment | 2019

von Niraula, S. | Gyawali, B.

2

Duration of adjuvant immunotherapy-biologic, clinical and economic considerations

enthalten in: Medical oncology (Northwood, London, England) | 2018

von Stav, I. | Gyawali, B. | Goldstein, D.

3

Duration of adjuvant immunotherapy—biologic, clinical and economic considerations

enthalten in: Medical oncology | 2018

von Stav, I. | Gyawali, B. | Goldstein, D.

4

Duration of adjuvant immunotherapy—biologic, clinical and economic considerations

enthalten in: Medical oncology | 2018

von Stav, I. | Gyawali, B. | Goldstein, D.

5

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

enthalten in: Breast cancer research and treatment | 2018

von Niraula, S. | Gyawali, B.

6

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

enthalten in: Breast cancer research and treatment | 2018

von Niraula, S. | Gyawali, B.

7

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

enthalten in: Breast cancer research and treatment | 2018

von Niraula, S. | Gyawali, B.

8

Duration of adjuvant trastuzumab in HER2 positive breast cancer : Overall and disease free survival results from meta-analyses of randomized controlled trials

enthalten in: Cancer treatment reviews | 2017

von Gyawali, B. | Niraula, S.

9

Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials

enthalten in: Cancer treatment reviews

von Gyawali, B. | Niraula, S.

1
[1]